A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Commentary|Videos|June 4, 2024
Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer
Author(s)Jennifer Eads, MD
Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.
Advertisement
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine, discusses the neoadjuvant pathologic complete response (pCR) rate results from the phase 2/3 ECOG-ACRIN EA2174 trial (NCT03604991) investigating the addition of nivolumab (Opdivo) to neoadjuvant chemotherapy and radiation in patients with locoregional esophageal and gastroesophageal junction (GEJ) adenocarcinoma.
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The zanidatamab-plus-chemotherapy arm met its overall survival end point at the second interim analysis of the phase 3 HERIZON-GEA-01 trial.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5